ile 77 ock Code : 1093) 2025 Results Presentation IND approvals : North America (18) China (58) Mar. 2026 INNOVAT 2025 Updates Regulatory Updates New drugs approved (including new indications): Breakthrough Therapy Designations: Major Clinical Trial Progress New pivotal clinical trials: Shareholder Return Since the beginning of the year 2025, a total of HK$ 4 been repurchased (including HK$153 million for equity incentive plan). The full-year dividend per share is HK Z cents (including interim dividend of H ...